ALLO-329 — Interim data
late 2026
Dose escalation and lymphodepletion optimization are ongoing, and we expect to provide a clinical and translational data update in late 2026.Source filing
ALLO biotech catalysts & pipeline
ALLOGENE THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
Cemacabtagene Ansegedleucel (Cema-Cel) — Interim data
mid-2027
The next program update tied to the interim event-free survival (EFS) analysis is expected in mid-2027.Source filing
Cemacabtagene Ansegedleucel (Cema-Cel) — Clinical data readout
mid-2028
We anticipate completing enrollment of the randomized MRD-positive portion of ALPHA3 by the end of 2027, conducting an interim EFS analysis in mid-2027, and conducting the primary EFS analysis in mid-2028.Source filing